Synta Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that target specific thyroid hormone receptor pathways in the liver. These pathways are crucial regulatory mechanisms for a range of cardio-metabolic and fatty liver diseases, which have high unmet medical needs. The company's lead candidate, resmetirom (MGL-3196), is an orally administered, small molecule that selectively targets thyroid hormone receptors in the liver. This candidate has shown broad activity and a favorable safety profile, prompting the initiation of Phase 3 clinical studies. The primary study, MAESTRO-NASH, aims to resolve non-alcoholic steatohepatitis (NASH) and reduce liver fibrosis, with secondary goals including lowering LDL cholesterol. Another study, MAESTRO-NAFLD-1, focuses on non-alcoholic fatty liver disease (NAFLD). Synta Pharmaceuticals operates in the biopharmaceutical market, primarily serving patients with advanced liver conditions. The company generates revenue through the development and potential commercialization of its therapeutic candidates.

Keywords: biopharmaceutical, thyroid hormone, liver diseases, cardio-metabolic, NASH, NAFLD, resmetirom, clinical trials, therapeutics, unmet medical need.